Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Ties Up with Servier for Commercialization of Latuda in Australia
July 16, 2015
- Takeda Files NDA for Novel Proteasome Inhibitor Ixazomib in US
July 16, 2015
- As 80% Era Looms, 3 Generic Majors Will Emerge as Dominant Suppliers: Sawai
July 16, 2015
- Kowa Grants Chugai Exclusive Marketing Rights in Japan for Peretinoin for Prevention of Recurrence of HCC
July 15, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
- Takeda Announces Its Plan to Improve Business Practices; Will Add an Outside Expert to Review Board
July 14, 2015
- US FDA Approves Novel Antipsychotic Agent Rexulti: Otsuka, Lundbeck
July 14, 2015
- Merck Serono Names Former Allergan Japan President Leo Lee as New President
July 14, 2015
- BIKEN to Map Out 5-Year Biz Plan, Eyes Collaboration for PIII: Director
July 13, 2015
- BIKEN to Produce and Ship Same Amount of Seasonal Flu Vaccines as Last Season: Director Yamanishi
July 13, 2015
- Takeda Submits Plans to Improve Business Practices
July 13, 2015
- Generic Share Increases to 52.0% in FY2014: JGA
July 13, 2015
- MTPC Files for Partial Change to Remicade Dosage for Psoriasis
July 13, 2015
- Hisamitsu Starts PII/III Study of Analgesic Transdermal Patch in Japan
July 13, 2015
- “Equal Sense of Gratitude and Responsibility” in Wake of New Generic Share Target of 80%: Nippon Chemiphar President
July 10, 2015
- Lilly Japan, Sumitomo Dainippon to Collaborate in Sales of Once-Weekly GLP-1 Receptor Agonist
July 10, 2015
- AZ Divests Rights to Develop, Sell GI Treatment Entocort Worldwide Excluding US to Tillotts
July 10, 2015
- Anti-PCSK9 Antibody Demonstrates Favorable Results in PIII Study for Japanese Patients: Sanofi, Regeneron
July 10, 2015
- Doctors Desire New Drugs for Dementia in Japan: Survey
July 9, 2015
- AbbVie to Initiate Clinical Study of Antibody-Drug Conjugate ABT-414 for Malignant Glioma in Japan
July 9, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…